Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ROIV Roivant Sciences Ltd

10,83

-0,08 (-0,73%)

26 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Roivant Sciences Charts.

Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Roivant Sciences Charts.

News Roivant Sciences Ltd

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 31 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Donnerstag 30 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 30 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 30 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Donnerstag 30 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
Donnerstag 16 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Dienstag 2 April 2024 (3 Monate vor) • GlobeNewswire Inc.

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Dienstag 26 März 2024 (3 Monate vor) • PR Newswire (US)

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Dienstag 13 Februar 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere Roivant Sciences Ltd News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen